Mount Sinai Researchers Discover Potential Boost to Cancer Immunotherapy

NEW YORK, March 30, 2020 /PRNewswire-PRWeb/ -- Mount Sinai researchers have discovered a pathway that regulates special immune system cells in lung cancer tumors, suppressing them and allowing tumors to grow. The scientists also figured out how to interrupt this pathway and ramp up the immune system to prevent tumor formation or growth, offering a potential boost to immunotherapy, according to a study published in Nature in March.

Researchers analyzed human and mouse lung cancer lesions, specifically studying the highly specialized immune cells called dendritic cells, which are considered the generals of the immune system. Dendritic cells give other immune system cells, called T-cells, identifying information from tumors so the T-cells can recognize and fight the cancer. Certain genetic material in the tumors, however, tamps down the dendritic cells' function via this newly discovered immune regulatory pathway.

Scientists performed high-tech, single-cell sequencing and high-definition imaging on mouse and human tumors to study the dendritic cells' activity in lung cancer and adjacent noncancerous lung tissues. They identified a molecular pathway that dampens dendritic cells' ability to program T-cells to kill. This study also showed that reversing this pathway significantly improves tumor responses in animals.

Based on the findings, scientists are designing a clinical trial that they expect will enhance patients' response to an immunotherapy called checkpoint blockade, by adding a second therapy that blocks the immune regulatory pathway that decreases dendritic cells' function in tumors. Right now only about 20 percent of patients respond to checkpoint blockade therapies. The trial will be done in collaboration with Regeneron Inc.

"This study highlights the power of single-cell technologies to identify new therapeutic targets in cancer," said senior author Miriam Merad, MD, PhD, Director of the Precision Immunology Institute and Mount Sinai Professor in Cancer Immunology at the Icahn School of Medicine at Mount Sinai, Co-leader of the Cancer Immunology Program at The Tisch Cancer Institute at Mount Sinai, and Director of the Mount Sinai Human Immune Monitoring Center.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care?from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

SOURCE Mount Sinai Health System